Safety And Efficacy Of Oral Versus Inhaled Corticosteroid For Moderate Persistent Asthma In Children 6 To 15 Years Old: A Randomized Controlled Trial

Yandee  V. Estrera,; Jemaila  B. Valles,; Josy Naty  M. Venturina,; Arnel Gerald  Q. Jiao,

Safety And Efficacy Of Oral Versus Inhaled Corticosteroid For Moderate Persistent Asthma In Children 6 To 15 Years Old: A Randomized Controlled Trial

Yandee V. Estrera | Jemaila B. Valles | Josy Naty M. Venturina | Arnel Gerald Q. Jiao

Abstract:

BACKGROUND: One out of 10 Filipino children suffer from bronchial asthma. Its increasing prevalence over the past decades causes significant morbidity to the patients and their families, especially when it is uncontrolled. In developing countries, the form of medicine, cost and access to medications are significant factors in achieving good control of symptoms. No study has been done to determine if the use of low dose oral corticosteroid is a safe and effective alternative treatment for children with asthma. OBJECTIVE: To compare the safety and efficacy of oral versus inhaled corticosteroid in moderate persistent asthma. METHODS: An open label randomized controlled trial was carried out in 40 patients 6 to 15 years old with newly diagnosed moderate persistent asthma. They were assigned to either inhaled or oral corticosteroid group. Efficacy of treatment based on daytime and nighttime coughing, limitation of activity, use of bronchodilators, FEV1, PEFR and level of asthma control were assessed. Safety of both treatment options were evaluated by the occurrence of corticosteroid induced hypertension, adrenal insufficiency and diabetes. RESULTS: The use of inhaled and oral corticosteroid showed improvement in daytime and nighttime cough, need for bronchodilators, limitation of activity, FEV1, PEFR and level of control. Furthermore, both treatment options had comparable safety profile. CONCLUSION: There was no significant difference on the safety and efficacy of oral versus inhaled corticosteroid in the long term treatment of moderate persistent bronchial asthma.

References:

Asher MI, Montefort S, Björkstén B, Lai CKW, Strachan DP, Weiland SK, Williams H. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Thorax. 2006;61(9):758–766.
Gustafson PM, Watson L, Davis KJ, Rabe KF. Poor asthma control in children: evidence from epidemiological surveys and implications for clinical practice. J Clin Pract. 2006;60:331–334.
Veronez A, Petrov E, Cserhati J, Hofman N, Geppe J, Medley S, Hughes. Fluticasone propionate in asthma: a long-term dose comparison study. Arch Dis Child. 2003;88:503–509.
Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) guidelines. 2008:2–8.
Chernick V, Boat T. Disorders of the respiratory tract in children. 7th ed. Philadelphia: WB Saunders; p. 808–810.
Neffen H, et al. Pan American J Public Health. 2005;17:191–197.
Braan SS. Chest. 2006;130:4S–12S.
Canadian Pediatric Asthma Consensus Guidelines 2004. Canadian Medical Association Journal. 2005;173.
Dawood OT, Ibrahim MIM, Palaiian S. Medication compliance among children. World J Pediatr. 2010;6(3):15–.
Mash BRI, Bheekie A, Jones P. Inhaled versus oral steroids for adults with chronic asthma. Cochrane Database Syst Rev. 2001;1:CD002160. doi:10.1002/14651858.CD002160.
De Benedictis FM, Bush A. Corticosteroids in respiratory diseases in children. Am J Respir Crit Care Med. 2012;185:12–23.
National Institutes of Health, National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda (MD): NIH; 1997. Publication No. 97-4051.
Gharaiboulou M, Kompani F, Morahedi M. Comparison between PEFR and FEV1 in the evaluation of children suspected to have asthma. Iranian Journal of Allergy, Asthma and Immunology. 2004;3:21–24.
Meltzer A, Smolensky MH, Alonzo GE, Harrist RB, Scott PH. An assessment of peak expiratory flow as a surrogate measurement of FEV1 in stable asthmatic children. Chest. 1989;96:329–333.
British guidelines on asthma management. Thorax. 1997;52(Suppl 1):S1–S21.
Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159:941–955.
Simmons LK, Molyneaux L, Yue DK, Chua EL. Steroid-induced diabetes: Is it just unmasking of type 2 diabetes? ISRN Endocrinol. 2012;Article ID 910765.
Trence DL. Management of patients on chronic glucocorticoid therapy: an endocrine perspective. Prim Care Clin Office Pract. 2003;30:593–605.
Santiago AH, Ratzan S. Acute adrenal crisis in an asthmatic child treated with inhaled fluticasone propionate. International Journal of Pediatric Endocrinology. 2010;2010.
Zollner EW. Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled corticosteroids (Part 2): the risk as determined by gold standard adrenal function tests: a systematic review. Pediatr Allergy Immunol. 2007;18:469–474.
Ursulla C, Maccartner D, Pollart S. American Family Physician. 2005;71(10).